JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033 - Avant Technologies ( OTC:AVAI ) , Annovis Bio ( NYSE:ANVS )
NEW YORK, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focused health.
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott ...
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( NASDAQ:ZYME ) , a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott ...
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced a novel strategic initiative ...
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets - Zymeworks ( NASDAQ:ZYME )
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer - Jazz Pharmaceuticals ( NASDAQ:JAZZ )
Jazz Pharmaceuticals Plc ( NASDAQ:JAZZ ) shares are popping on Monday following the company's positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive ...
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans - Jazz Pharmaceuticals ( NASDAQ:JAZZ ) , BeOne Medicines ( NASDAQ:ONC ) , Zymeworks ( NASDAQ:ZYME )
Zymeworks Inc. ( NASDAQ:ZYME ) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Alto Neuroscience ( NYSE:ANRO ) , Albemarle ( NYSE:ALB )
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday.
Why Jazz ( JAZZ ) International Revenue Trends Deserve Your Attention
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® ( zanidatamab-hrii ) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
VANCOUVER, British Columbia, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
- Former Chimerix ( CMRX, acquired by Jazz for $935 million ) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic ...
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Surrozen, Inc. ( "Surrozen" or the "Company" ) ( Nasdaq: SRZN ) , a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye ...
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Jazz Pharma ( JAZZ ) Earnings Call Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETPresident and Chief Executive Officer - Renee GalaContinue reading ...
Jazz Pharmaceuticals ( JAZZ ) Q3 Earnings and Revenues Beat Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of +41.64% and +2.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
Earnings Preview: Jazz Pharmaceuticals ( JAZZ ) Q3 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Announces Participation in Upcoming Investor Conferences - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( NASDAQ:ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
VANCOUVER, British Columbia, Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , Jazz Pharmaceuticals ( NASDAQ:JAZZ ) , Alkermes ( NASDAQ:ALKS )
On Wednesday, Alkermes plc ( NASDAQ:ALKS ) agreed to acquire Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.
Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement
DUBLIN, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. ( "Jazz" ) .
Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement
DUBLIN, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( Nasdaq: AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. ( "Jazz" ) .
Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement - Avadel Pharmaceuticals ( NASDAQ:AVDL )
DUBLIN, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) , a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. ( "Jazz" ) .
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street - Aehr Test System ( NASDAQ:AEHR ) , Jazz Pharmaceuticals ( NASDAQ:JAZZ )
The S&P 600 Small Cap Index is only up 2.0% year-to-date, but the small-cap trajectory is trending to the upside, with the index returning 5.8% since July. That trend is a worldwide one, with a favorable mix of economic indicators currently working in favor of small-cap stocks.
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
VANCOUVER, British Columbia, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( NASDAQ:ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( NASDAQ:ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
FDA approves Roche's Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Basel, 3 October 2025 - Roche ( SIX: RO, ROG. OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration ( FDA ) has approved Tecentriq® ( atezolizumab ) and Tecentriq Hybreza® ( atezolizumab and hyaluronidase-tqjs ) in combination with lurbinectedin ( Zepzelca® ) for the ...
Crane NXT Announces Appointment of Kim DiMaurizio as Senior Vice President and Chief People Officer
WALTHAM, Mass., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Crane NXT, Co. ( NYSE: CXT ) ( "Crane NXT" or the "Company" ) , a premier industrial technology company, today announced it has appointed Kim DiMaurizio as Senior Vice President and Chief People Officer, effective October 1, 2025.
Crane NXT Announces Appointment of Kim DiMaurizio as Senior Vice President and Chief People Officer - Crane NXT ( NYSE:CXT )
WALTHAM, Mass., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Crane NXT, Co. ( NYSE:CXT ) ( "Crane NXT" or the "Company" ) , a premier industrial technology company, today announced it has appointed Kim DiMaurizio as Senior Vice President and Chief People Officer, effective October 1, 2025.
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.
Design Therapeutics Appoints Justin Gover to Board of Directors - Compass Pathways ( NASDAQ:CMPS ) , Design Therapeutics ( NASDAQ:DSGN )
CARLSBAD, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. DSGN, a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective ...
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
VANCOUVER, British Columbia, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Announces Participation in Upcoming Investor Conferences - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Onco360 adds Modeyso™ ( dordaviprone ) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ ( dordaviprone ) .
Artios Pharma Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib ( ART0380 ) into Late-stage Development
Mike Andriole brings approximately 25 years of experience in the biopharmaceutical industry and a successful track record of delivering new first-in-class oncology therapies in indications of high unmet need to patients where no approved treatment exists
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Don't Overlook Jazz ( JAZZ ) International Revenue Trends While Assessing the Stock
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Jazz ( JAZZ ) Q2 Revenue Rises 2%
Jazz Pharmaceuticals ( NASDAQ:JAZZ ) is a global biopharmaceutical company focused on innovative therapies for neuroscience and rare oncology diseases. On August 5, 2025, it reported second quarter results for fiscal 2025.
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.
Jazz Pharmaceuticals ( JAZZ ) Reports Q2 Loss, Misses Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
